R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer Clinical Trial

Official title:

A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00773955
• Other study ID #: NCI-2009-01058
• Secondary ID: NCI-2009-01058MA
• Status: Completed
• Phase: Phase 2
• First received: October 15, 2008
• Last updated: April 23, 2014
• Start date: November 2008
• Est. completion date: August 2010

Study information

• Verified date: October 2011
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Description:

PRIMARY OBJECTIVES:

I. To determine the objective response rate of R-(-)-gossypol in patients with recurrent chemotherapy-sensitive extensive stage small cell lung cancer.

II. To determine the time to disease progression. III. To determine the overall survival. IV. To assess the toxicities associated with this drug. V. To explore whether intratumoral Bcl-2 family member expression correlates with sensitivity to targeting by R-(-)-gossypol.

VI. To explore whether the administration of R-(-)-gossypol causes specific induction of the intrinsic apoptotic pathway.

OUTLINE: This is a multicenter study.

Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Blood is collected periodically during treatment for pharmacodynamic analysis. Peripheral blood mononuclear cells are analyzed via protein isolation and western blotting for Bcl-2, cytoplasmic release of cytochrome c, and caspase activation. Available tumor tissue blocks are assessed by immunohistochemistry.

After completion of study therapy, patients are followed periodically for up to 5 years.

Other known NCT identifiers

• NCT01647113

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: August 2010
• Est. primary completion date: October 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed small cell lung cancer

• Extensive stage disease

• Recurrent disease

• Measurable disease

• Chemotherapy-sensitive disease, defined as:

• No progression during first-line chemotherapy

• No disease recurrence < 2 months after completion of first-line chemotherapy

• Must have received prior platinum-based chemotherapy

• No symptomatic or progressive brain metastases

• Patients with previously treated brain metastases who are clinically and radiographically stable or improved and have been off steroids = 14 days are eligible

• ECOG performance status 0-2

• Life expectancy > 12 weeks

• Leukocytes = 3,000/µL

• ANC = 1,500/µL

• Platelet count = 100,000/µL

• Total bilirubin < 1.5 mg/dL

• AST and ALT = 2.5 times upper limit of normal

• Serum creatinine = 1.5 mg/dL OR creatinine clearance = 60 mL/min

• Hemoglobin > 8 g/dL

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception before, during, and for 30 days after completion of study therapy

• Able to take oral medications on a regular basis

• Willing to provide blood samples for mandatory correlative studies

• No condition that impairs the ability to swallow and retain R-(-)-gossypol tablets, including the following:

• Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation

• Active peptic ulcer disease

• No malabsorption syndrome or disease significantly affecting gastrointestinal function

• No ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction

• No uncontrolled concurrent illness including, but not limited to, any of the following:

• Ongoing or active infection

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Cardiac arrhythmia

• Psychiatric illness or social situations that would limit compliance with study requirements

• No symptomatic hypercalcemia > grade 2

• No requirement for routine use of hematopoietic growth factors (including G-CSF, GM-CSF, or IL-11) or platelet transfusions to maintain ANC or platelet counts

• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to R-(-)-gossypol

• No HIV positivity

• Recovered from all prior therapy, including prior surgical procedures

• No prior surgical procedures affecting absorption

• No prior resection of the stomach or small bowel

• No more than one prior chemotherapy regimen

• No prior racemic gossypol or R-(-)-gossypol

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

• At least 4 weeks since prior radiotherapy, hormonal agents, or biologic response modifiers

• At least 4 weeks since prior and no concurrent investigational agents or devices

• No concurrent prophylactic hematopoietic growth factors (including filgrastim [G-CSF], sargramostim [GM-CSF], or interleukin-11 [IL-11]) during course one

• No concurrent combination antiretroviral therapy for HIV-positive patients

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Extensive Stage Small Cell Lung Cancer
• Lung Neoplasms
• Recurrent Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• R-(-)-gossypol acetic acid
Given orally

Other:
• pharmacological study
Correlative studies
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR)	The number of successes will be estimated by counting the number of participants with confirmed responses. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart.; Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: A Complete Response (CR) requires the disappearance of all target lesions; A Partial Response (PR) requires a >=30% decrease in the sum of the longest diameter of target lesions from baseline measurements.	During the first 6 courses of treatment	No
Secondary	Survival Time	Estimated using the method of Kaplan-Meier.	From registration to death due to any cause, assessed up to 5 years	No
Secondary	Time to Disease Progression	Time to disease progression is defined as the time from registration to the earliest date documentation of disease progression. Estimated using the method of Kaplan-Meier.; Per the RECIST criteria, progression is defined as at least a 20% increase in the sum of Longest Dimension (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	From registration to the earliest date documentation of disease progression, assessed up to 5 years	No
Secondary	Duration of Response		From the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented, assessed up to 5 years	No